Form D · Pharmaceuticals
ALIMERA SCIENCES INC
Alpharetta, GA · CIK 0001267602
Offering snapshot reported May 31, 2023 · SEC filing
- Reported sold
- $81M Offering amount: $81M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 24, 2023 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$12,000,000 → $81,000,000
- Reported investors4 → 16
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 31, 2023 | Amendment | $81,000,000 | $69,000,000vs Apr 7, 2023 | 16 | SEC filing |
| Apr 7, 2023 | Initial | $12,000,000 | No comparison | 4 | SEC filing |
| Apr 27, 2021 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Feb 18, 2014 | Initial | $37,500,000 | No comparison | 21 | SEC filing |
| Oct 5, 2012 | Initial | $40,000,000 | No comparison | 0 | SEC filing |
| May 25, 2011 | Initial | $332,486 | No comparison | 0 | SEC filing |
| Sep 4, 2009 | Initial | $5,000,000 | No comparison | 25 | SEC filing |
| Mar 31, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 5, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-478298
The amounts set forth in Item 13(a) and 13(b) represent a two tranche closing. The first tranche, consisting of $12,000,000 of securities closed on 03/24/2023 and the second tranche, consisting of $69,000,000 of securities closed on 05/17/2023.
Source: Form D, filed May 31, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Philip Ashman | Executive |
| Glen Bradley | Director |
| Mark Brooks | Director |
| Susan Caballa | Executive |
| Richard S. Eiswirth | Director, Executive |
| Richard S. Eiswirth, Jr. | Director, Executive |
| Kenneth Green | Executive |
| Brian K. Halak | Director |
| David Holland | Executive |
| Anders Hove | Director |
| J. Philip Jones | Executive |
| Michael Kaseta | Director |
| Garheng Kong | Director |
| James R. Largent | Director |
| Adam Morgan | Director |
| Charles Daniel Myers | Director, Executive |
| C. Daniel Myers | Director |
| Daniel Myers | Director |
| Erin Parsons | Director |
| Peter J. Pizzo | Director |
| Peter J. Pizzo Iii | Director |
| Calvin Roberts | Director |
| Roger Sawheny | Director |
| Russell Skibsted | Executive |
| John Snisarenko | Director |
| Mary T. Szela | Director |
| Philip Tracy | Director |
| Phil Tracy | Director |
| Bryce Youngren | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
6310 Town Square Suite 400
Alpharetta, GA, 30005
Alpharetta, GA, 30005